CCM
DMAA

Context Capital Management’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

Context Capital Management’s Portfolio DMAA Stock Details DMAA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.62M Hold
250,000
– – 0.06% 156
2025
Q4 		$2.59M Hold
250,000
– – 0.07% 136
2025
Q3 		$2.57M Buy
+250,000
New +$2.56M 0.08% 128

Other funds holding DMAA

KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Context Capital Management's DMAA Position: Q1 2026 in Review

Context Capital Management held its Drugs Made In America Acquisition Corp (DMAA) position steady in Q1 2026 at 250,000 shares worth $2.62M. The position accounts for 0.06% of the portfolio, ranked #156.

Context Capital Management first reported a position in DMAA in Q3 2025 and has held it in 3 quarters since. 39 funds tracked by Wall St. Rank hold DMAA as of Q1 2026.

  • Context Capital Management held 250,000 shares of Drugs Made In America Acquisition Corp worth $2.62M as of Q1 2026.
  • Context Capital Management left its Drugs Made In America Acquisition Corp share count unchanged in Q1 2026.
  • Drugs Made In America Acquisition Corp made up 0.06% of Context Capital Management's portfolio in Q1 2026, its #156 holding.
  • Context Capital Management first reported a position in Drugs Made In America Acquisition Corp in Q3 2025 and has held it in 3 quarters since.
  • 39 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q1 2026.

Based on Context Capital Management's 13F filing for Q1 2026, filed 7 May 2026.